步长制药(603858.SH)：全资子公司撤回药品上市许可注册申请

Core Viewpoint - The company announced the withdrawal of the drug registration application for "Empagliflozin Tablets" due to the need for further improvement of the submission materials [1] Group 1 - The company's wholly-owned subsidiary, Shandong Danhong, received a termination notice from the National Medical Products Administration regarding the drug registration application for "Empagliflozin Tablets" [1] - The decision to withdraw the application was made after careful consideration, indicating a strategic approach to ensure compliance with regulatory requirements [1] - The company plans to resubmit the drug registration application after completing the necessary research and improvements, clarifying that this withdrawal does not signify the termination of the project [1]